HUP9801917A2 - Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására - Google Patents

Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására

Info

Publication number
HUP9801917A2
HUP9801917A2 HU9801917A HUP9801917A HUP9801917A2 HU P9801917 A2 HUP9801917 A2 HU P9801917A2 HU 9801917 A HU9801917 A HU 9801917A HU P9801917 A HUP9801917 A HU P9801917A HU P9801917 A2 HUP9801917 A2 HU P9801917A2
Authority
HU
Hungary
Prior art keywords
vaccine
preparation
immunogenic construct
immunogenic
flavivirus
Prior art date
Application number
HU9801917A
Other languages
English (en)
Inventor
Martha Eibl
Heinz Leibl
Josef W. Mannhalter
Original Assignee
Immuno Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7764404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9801917(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Aktiengesellschaft filed Critical Immuno Aktiengesellschaft
Publication of HUP9801917A2 publication Critical patent/HUP9801917A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány imműnőgén készítményekre vőnatkőzik, amelyek (i) egyinaktivált flavivírűst vagy annak származékát, valamint (ii) legalábbegy imműnőgén kőmpőnenst tartalmaznak, amely a flavivírűshőz van kötvevagy azzal együtt adszőrbeáltatva. A találmány tővábbá az imműnőgénkészítmények előállítására szőlgáló eljárásra és alkalmazásűkravőnatkőzik. ŕ
HU9801917A 1995-06-14 1996-05-15 Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására HUP9801917A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19521705A DE19521705C2 (de) 1995-06-14 1995-06-14 Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine

Publications (1)

Publication Number Publication Date
HUP9801917A2 true HUP9801917A2 (hu) 1998-11-30

Family

ID=7764404

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801917A HUP9801917A2 (hu) 1995-06-14 1996-05-15 Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására

Country Status (8)

Country Link
US (1) US6372221B2 (hu)
EP (1) EP0833923B2 (hu)
JP (1) JPH11507545A (hu)
AT (1) ATE246250T1 (hu)
CA (1) CA2224645A1 (hu)
DE (2) DE19521705C2 (hu)
HU (1) HUP9801917A2 (hu)
WO (1) WO1997000322A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6589531B1 (en) 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US20040185055A1 (en) * 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
US7722885B2 (en) * 2002-07-26 2010-05-25 National Science And Technology Development Agency Dengue virus mutant strain MBU 01-2002
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
NZ564375A (en) * 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
CA2960659C (en) 2007-11-09 2021-07-13 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
JP5511660B2 (ja) * 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006334A (en) * 1973-05-07 1991-04-09 The Ohio State University Antigenic modification of polypeptides
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69230316T2 (de) * 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
JPH06100465A (ja) * 1992-09-24 1994-04-12 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの組み換え生ワクチン
DE4426622C1 (de) * 1994-07-27 1996-02-22 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben

Also Published As

Publication number Publication date
US6372221B2 (en) 2002-04-16
JPH11507545A (ja) 1999-07-06
WO1997000322A1 (de) 1997-01-03
EP0833923B2 (de) 2010-03-17
DE19521705C2 (de) 1997-10-09
EP0833923A1 (de) 1998-04-08
DE19521705A1 (de) 1996-12-19
ATE246250T1 (de) 2003-08-15
DE59610629D1 (de) 2003-09-04
US20010009669A1 (en) 2001-07-26
EP0833923B1 (de) 2003-07-30
CA2224645A1 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
IT1262896B (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
AR001686A1 (es) Una composición vacuna un proceso para prepararla y su uso para la fabricación de una vacuna
DE69531699D1 (de) Cyclodextrinderivate und verfahren zu deren herstellung
WO2001034801A3 (en) Recombinant gelatin in vaccines
HUP9900919A2 (hu) 2,5-D-Mannóz-csoportot tartalmazó B antigén csoportba tartozó II és III típusú streptococcus poliszacharid-fragmentumok és ezeket tartalmazó vakcinakonjugátumok
CY1106206T1 (el) Φαρμακευτικη συνθεση πepιεχουσα φενοφιβρατη και μεθοδος παρασκευης της
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
HUP9801242A1 (hu) Hepatitis B vakcina
FI932626A (fi) Av en patogenisk aemne haerledande antigenisk polysackarid deriverad oligosackarid
FI951468A (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
NO942771L (no) Oljebasert og vannbasert hjelpestoff-blanding
HUP9903931A2 (hu) Indolopirrolokarbazolok citotoxikus aminocukor- és más rokon jellegű cukorszármazékai
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
DE69231663T2 (de) Polysaccharid-protein-konjugate
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DK0792165T3 (da) Immunogene præparater
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
ES2089923T3 (es) Composicion de vacuna subunitaria recombinante viva y procedimiento de preparacion.
HUP0104881A2 (hu) Eljárás inaktivált "víz az olajban" emulzióval adjuvált vakcinák előállítására
ATE67212T1 (de) Thiazolidin-4-carbonsaeurederivat, seine herstellung und pharmazeutische zusammensetzungen, die dieses enthalten.
YU234690A (sh) Supstituisani 4-fenil-4-piperidinkarboksamidi i postupak za njihovo dobijanje
PL286898A1 (en) Method of obtaining a conjugated vaccine against streptococcus of b group, method of obtaining a recombined molecule and method of obtaining a protein of atreptococcus o b group
MY126520A (en) A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same